Approval · Notice of Compliance 19080 · 2017
PROLENSA: Notice of Compliance 19080
Issued February 8, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19080
- Date
- February 8, 2017
- Company
- Bausch & Lomb Inc.Rochester, New York, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the in-use statement in the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROLENSA | Not yet assigned | — |
Medicinal ingredients
- BROMFENAC SODIUM SESQUIHYDRATE 0.805 MG per ML